Experts look back at a glioblastoma study and ask what should come next
Original title: Beyond Dose Escalation in Glioblastoma: Lessons Learned from INTRAGO-II and the Case for Targeting Tumor Biology.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is experts sharing views on where research should go, not a new result.
The short version
This article looks back at an earlier study and suggests a new direction for glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary research.
What was studied. This is a written piece about glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary, a type of brain tumor. It looks back at an earlier study called INTRAGO-II, which tried giving higher doses of treatment.
What they found. No summary of this article was available, so we cannot report its details. From its title, the authors argue that raising the dose alone may not be enough. They make the case for treatments aimed at how the tumor itself works.
What this means, and what it doesn't
What it could mean: Researchers may be moving away from simply giving stronger doses. They may focus more on the tumor's own makeup. This could shape which treatments get tested in the future.
What it doesn't mean: This is an opinion and review piece, not a new test of a treatment. It does not offer a new treatment you can get today. It does not change current care, and it is not a cure. Talk with your care team about what is right for you.
Source: PubMed, September 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.